Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma
暂无分享，去创建一个
W. Lowrance | R. Figlin | C. Wood | V. Master | R. Uzzo | M. Debenedette | G. Bratslavsky | David Y. T. Chen | N. Tannir | S. Tykodi | A. Kapoor | D. Vaena | A. Plachco | I. Tcherepanova | A. Gamble | C. Nicolette | J. Horvatinovich | Marcus Norris | Marcus S. Norris